%0 Journal Article
%A Mai, Elias K
%A Benner, Axel
%A Bertsch, Uta
%A Brossart, Peter
%A Hänel, Annette
%A Kunzmann, Volker
%A Naumann, Ralph
%A Neben, Kai
%A Egerer, Gerlinde
%A Ho, Anthony D
%A Hillengass, Jens
%A Raab, Marc S
%A Neubauer, Andreas
%A Peyn, Astrid
%A Ko, Yon-Dschun
%A Peter, Norma
%A Scheid, Christof
%A Goldschmidt, Hartmut
%T Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
%J British journal of haematology
%V 173
%N 5
%@ 0007-1048
%C Oxford [u.a.]
%I Wiley-Blackwell55962
%M DKFZ-2017-05110
%P 731 - 741
%D 2016
%X The prospective, randomized phase III trial GMMG-HD2 aimed at demonstrating non-inferiority of single (Arm A) versus tandem (Arm B) high-dose melphalan followed by autologous transplantation (HDM/ASCT) with regard to 2-year event-free survival (EFS) in newly-diagnosed multiple myeloma (MM) and included 358 evaluable patients [Intention-to-treat population, (ITT), single/tandem HDM/ASCT: n = 177/181]. After a median follow-up of more than 11 years, non-inferiority of single versus tandem HDM/ASCT was demonstrated using the planned non-inferiority threshold of 15
%K Myeloablative Agonists (NLM Chemicals)
%K Melphalan (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:26990892
%R 10.1111/bjh.13994
%U https://inrepo02.dkfz.de/record/129105